+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Abemaciclib"

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Estrogen Receptor Beta (ER Beta or Nuclear Receptor Subfamily 3 Group A Member 2 or NR3A2 or ESR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • August 2022
  • 78 Pages
  • Global
From
Loading Indicator

Abemaciclib is a type of oncology drug used to treat certain types of cancer. It is a cyclin-dependent kinase (CDK) inhibitor, which works by blocking the activity of certain proteins that are involved in the growth and spread of cancer cells. Abemaciclib is used in combination with other cancer treatments, such as hormone therapy, chemotherapy, and targeted therapy. It is approved for the treatment of advanced or metastatic breast cancer, as well as for the treatment of non-small cell lung cancer. Abemaciclib is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2017. It is the first CDK inhibitor to be approved for the treatment of advanced or metastatic breast cancer. Since its approval, it has become an important part of the oncology drug market. Several companies are involved in the Abemaciclib market, including Eli Lilly and Company, Novartis, and Pfizer. These companies are involved in the research, development, and marketing of Abemaciclib. Show Less Read more